Communiqués Sysmex Corporation

Actions

6869

JP3351100007

Equipement, fournitures et distribution médicale

Marché Fermé - Japan Exchange Autres places de cotation 08:30:00 17/07/2026			Varia. 5j.	Varia. 1 janv.
1 628,00 ^JPY	+4,96%		+6,34%	+5,54%

17/06	VolitionRx Limited et Sysmex Corporation annoncent une collaboration pour optimiser le test Nu.Q NETs H3.1 sur la plateforme Sysmex	CI
17/06	VolitionRx collabore avec le japonais Sysmex pour l'optimisation de sa plateforme	MT

Communiqués

17/07	Sysmex : HIGH DIAGNOSTIC PERFORMANCE OF THE RANDOM-ACCESS HISCL pTAU-217, Aβ42 AND Aβ40 PLASMA ASSAYS IN DETECTING AMYLOID PATHOLOGY ACROSS CLINICAL STAGES	PU
17/07	Sysmex : Plasma Endogenously Cleaved MTBR‑tau243 Measured By An Automated Immunoassay Is Associated With Tau PET-based Braak Staging	PU
17/07	Sysmex : Longitudinal Changes in Blood-Based Biomarkers of Alzheimer’s Disease Across Age Groups and Their Associations with Cognitive Function	PU
17/07	Validation Of Highly Specific And Automated Immunoassays For Endogenously Cleaved MTBR-tau243 In CSF: A Comparison With Mass Spectrometry	PU
16/07	Sysmex : Presenting at the Alzheimer’s Association International Conference 2026 (AAIC 2026)	PU
14/07	Assessment of aspirin response in neuroendovascular patients: comparison of five platelet function tests across light transmission aggregometry and a cartridge-based assay	PU
14/07	Sysmex : Assessment of Platelet Function Between Low-Dose Prasugrel and Clopidogrel in Patients Undergoing Neuroendovascular Treatment	PU
14/07	Sysmex : Method Comparison of the Revohem Anti-Xa LRT assay Compared to Other Commercial Reagents – Monitoring of Xa-Direct oral anticoagulants	PU
01/07	Sysmex : Genetic Testing Using Sysmex’s Assay Kit Receives Insurance Coverage as the First of Its Kind in Japan for Assessing the Risk of Adverse Reactions to Anti-Amyloid β Antibody Drugs	PU
29/06	Sysmex : Selected as One of the World's Most Sustainable Companies 2026 by TIME	PU
26/06	Sysmex : Notice of Resolutions at the 59th Ordinary General Meeting of Shareholders	PU
14/05	Sysmex : Financial Statements( PDF format / 306KB )	PU
14/05	Sysmex : Presentation( PDF format / 1.1MB )	PU
14/05	Sysmex : Financial Data( PDF format / 741KB )	PU
14/05	Sysmex : Notice Regarding Dividends from Surplus	PU
14/05	Sysmex : Announcement of Executive Changes	PU
08/05	Sysmex : Notice Concerning the Status of Acquisition of Treasury Stock	PU
07/05	Sysmex : Included in S&P Dow Jones Indices’ Global ESG Index for the 10th Consecutive Year	PU
28/04	Sysmex : Announcement Regarding Impairment Losses (Consolidated Financial Results), as well as Revision of Full-Year Financial Forecast for the Fiscal Year Ending March 31, 2026	PU
23/03	Sysmex : Identification of Serum IL‑22 and IL‑18 as Cytokines Reflecting Disease Activity in Atopic Dermatitis During Dupilumab Therapy- Potential for New Monitoring Indicators Accounting for Diverse Inflammatory Patterns	PU
23/03	[Conference Presentation] Presenting the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders: AD/PD™ 2026	PU
19/03	Sysmex : Script file( PDF format / 3.3MB )	PU
19/03	Sysmex : Mid-Term Management Plan Q&A Script file( PDF format / 122KB )	PU
10/03	Sysmex : Presenting the AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases	PU
05/03	Sysmex : Announcement of Organizational and Personnel Changes	PU